结合疫苗市场 - 全球产业规模、份额、趋势、机会和预测，按产品类型、疾病适应症、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球结合疫苗市场价值为 196.9 亿美元，预计到 2030 年将达到 341 亿美元，年复合成长率(CAGR) 为 9.56%。这一显着的市场扩张是由人们对预防性医疗保健的日益重视所推动的。世界各国政府和医疗保健组织都致力于提高免疫覆盖率，以减少肺炎球菌感染、B型流感嗜血桿菌 (Hib) 和脑膜炎球菌疾病等传染病的流行。全球医疗支出的增加以及已开发国家和发展中国家对疫苗接种计划的优先重视为市场成长创造了有利的环境。此外，对单一配方针对多种病原体的疫苗的需求刺激了多价结合疫苗的开发，这种疫苗可以在提高成本效益的同时提供全面的保护。人们越来越意识到疫苗在预防危及生命的疾病方面的作用，特别是在婴儿和老年人等脆弱人群中，这进一步促进了市场扩张。

主要市场驱动因素

提高预防保健意识

主要市场挑战

製造成本高

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第四章：全球结合疫苗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品类型（单价合併疫苗、多价合併疫苗）
  • 依疾病指征（肺炎链球菌、流感、脑膜炎双球菌、伤寒）
  • 按最终使用者（医院和诊所、门诊护理中心、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 依产品类型
  • 按疾病指征
  • 按最终用户
  • 按地区

第五章：亚太地区结合疫苗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依产品类型
  • 按疾病指征
  • 按最终用户
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第六章：欧洲结合疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美结合疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲结合疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 9 章：中东和非洲结合疫苗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 埃及

第 10 章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 12 章：全球结合疫苗市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Sanofi SA
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG

第 15 章：策略建议

第16章 调査会社について・免责事项

The Global Conjugate Vaccine Market was valued at USD 19.69 billion in 2024 and is projected to reach USD 34.10 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.56%. This significant market expansion is driven by the increasing recognition of preventive healthcare. Governments and healthcare organizations globally are focused on improving immunization coverage to reduce the prevalence of infectious diseases such as pneumococcal infections, Haemophilus influenzae type b (Hib), and meningococcal diseases. Rising global healthcare spending and the prioritization of vaccination programs in both developed and developing nations have created a favorable environment for market growth. Additionally, the demand for vaccines targeting multiple pathogens in a single formulation has spurred the development of multivalent conjugate vaccines, which offer comprehensive protection while enhancing cost-effectiveness. The growing awareness of vaccines' role in preventing life-threatening diseases, particularly among vulnerable populations like infants and the elderly, has further contributed to market expansion.

Key Market Drivers

Increasing Awareness of Preventive Healthcare

The growing awareness of preventive healthcare is a crucial factor driving the expansion of the Global Conjugate Vaccine Market. In recent years, there has been a notable shift from a curative to a preventive healthcare approach. This shift is supported by the understanding that preventing diseases through vaccination is more cost-effective and less burdensome on individuals and healthcare systems than treating illnesses after they occur.

Key Market Challenges

High Manufacturing Costs

The manufacturing complexity of conjugate vaccines arises from their unique composition. These vaccines combine a weak antigen with a potent one to generate a stronger immune response. Achieving this requires advanced biotechnological techniques and strict quality control throughout production. Additionally, rigorous regulatory requirements further contribute to the overall production cost. High manufacturing costs limit the accessibility of conjugate vaccines, especially in low- and middle-income countries, where budget constraints often hinder vaccine procurement and affordability. Even in developed countries with robust healthcare systems, the high cost of conjugate vaccines can pose challenges, potentially deterring healthcare providers and individuals from prioritizing these vaccines, despite their proven efficacy.

Key Market Players

• Sanofi S.A.
• Pfizer Inc.
• Merck & Co., Inc.
• GlaxoSmithKline plc
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG

Report Scope

This report segments the Global Conjugate Vaccine Market by the following categories, along with detailed insights into industry trends:

By Product Type:

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines

By Disease Indication:

• Pneumococcal
• Influenza
• Meningococcal
• Typhoid

By End-User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

By Region:

• North America:
• United States
• Canada
• Mexico
• Europe:
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia-Pacific:
• China
• India
• Japan
• Australia
• South Korea
• South America:
• Brazil
• Argentina
• Colombia
• Middle East & Africa:
• South Africa
• Saudi Arabia
• UAE
• Kuwait
• Turkey
• Egypt

Competitive Landscape

The competitive landscape includes detailed profiles of the major companies operating in the Global Conjugate Vaccine Market.

Available Customizations

TechSci Research offers customizations for the Global Conjugate Vaccine Market report to suit specific business needs. Customization options include:

• Detailed analysis and profiling of up to five additional market players.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Conjugate Vaccine Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Product Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine)
  • 4.2.2. By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid)
  • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Product Type
  • 4.3.2. By Disease Indication
  • 4.3.3. By End-User
  • 4.3.4. By Region

5. Asia Pacific Conjugate Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type
  • 5.2.2. By Disease Indication
  • 5.2.3. By End-User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Conjugate Vaccine Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Product Type
      • 5.3.1.2.2. By Disease Indication
      • 5.3.1.2.3. By End-User
  • 5.3.2. India Conjugate Vaccine Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Product Type
      • 5.3.2.2.2. By Disease Indication
      • 5.3.2.2.3. By End-User
  • 5.3.3. Australia Conjugate Vaccine Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Product Type
      • 5.3.3.2.2. By Disease Indication
      • 5.3.3.2.3. By End-User
  • 5.3.4. Japan Conjugate Vaccine Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Product Type
      • 5.3.4.2.2. By Disease Indication
      • 5.3.4.2.3. By End-User
  • 5.3.5. South Korea Conjugate Vaccine Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Product Type
      • 5.3.5.2.2. By Disease Indication
      • 5.3.5.2.3. By End-User

6. Europe Conjugate Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Disease Indication
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Conjugate Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By End-User
  • 6.3.2. Germany Conjugate Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By End-User
  • 6.3.3. Spain Conjugate Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By End-User
  • 6.3.4. Italy Conjugate Vaccine Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By Disease Indication
      • 6.3.4.2.3. By End-User
  • 6.3.5. United Kingdom Conjugate Vaccine Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By Disease Indication
      • 6.3.5.2.3. By End-User

7. North America Conjugate Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Disease Indication
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Conjugate Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By End-User
  • 7.3.2. Mexico Conjugate Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By End-User
  • 7.3.3. Canada Conjugate Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By End-User

8. South America Conjugate Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Disease Indication
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Conjugate Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By End-User
  • 8.3.2. Argentina Conjugate Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By End-User
  • 8.3.3. Colombia Conjugate Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By End-User

9. Middle East and Africa Conjugate Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Disease Indication
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Conjugate Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By End-User
  • 9.3.2. Saudi Arabia Conjugate Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By End-User
  • 9.3.3. UAE Conjugate Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By End-User
  • 9.3.4. Egypt Conjugate Vaccine Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Product Type
      • 9.3.4.2.2. By Disease Indication
      • 9.3.4.2.3. By End-User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Conjugate Vaccine Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Sanofi S.A
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Merck & Co. Inc.
• 14.4. GlaxoSmithKline plc
• 14.5. Bharat Biotech International Limited
• 14.6. Serum Institute of India Pvt. Ltd
• 14.7. Biological E. Limited
• 14.8. Bavarian Nordic A/S
• 14.9. CSL Limited
• 14.10. Novartis AG

15. Strategic Recommendations

16. About Us & Disclaimer